Biotech news for Friday, May 8, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Earnings Call Insights: Palvella Therapeutics (PVLA) Q1 2026 Management view CEO Wesley Kaupinen said the company is “positioned for our first potential FDA approval and U.S. commercial launch,” citing “decisively positive Phase III results for QTORIN rapamyci…
Earnings Call Insights: Arcturus Therapeutics (ARCT) Q1 2026 Management View “The first quarter of 2026 was a period of solid execution for Arcturus as we continue to advance our rare disease pipeline and strengthen our leadership team,” said CEO Joseph Payne,…
Earnings Call Insights: Verastem (VSTM) Q1 2026 Management view “Since our launch in May 2025, we've seen steady growth quarter-over-quarter, achieving $18.7 million in net product revenue in Q1 with nearly $50 million in total net product revenue to date,” sa…
Earnings Call Insights: Vericel Corporation (VCEL) Q1 2026 Management View "The company generated record first quarter total revenue of more than $68 million, which increased 30% over last year and significantly exceeded our guidance for the quarter" (CEO, Pre…
Earnings Call Insights: Arrowhead Pharmaceuticals (ARWR) Q2 2026 Management View “Arrowhead is now on the strongest footing of our history. We are commercial.” (Chairman, CEO & President Dr. Christopher Anzalone) “We are now seeing around 30 new prescripti…
Earnings Call Insights: CytomX Therapeutics (CTMX) Q1 2026 Management View Dr. Sean McCarthy framed 2026 as “a transformational year for CytomX,” citing “excellent clinical progress with Varseta-M in late line colorectal cancer” and positioning Varseta-M as “t…
Earnings Call Insights: Zai Lab (ZLAB) Q1 2026 Management view CEO Ying Du framed the quarter as an inflection in global development, saying, "Zai Lab is at a pivotal moment," and linked the strategy to global execution and productivity, adding, "We are also l…
Earnings Call Insights: Ironwood Pharmaceuticals (IRWD) Q1 2026 Management View CEO Thomas McCourt said 2026 priorities remain “maximizing LINZESS, advancing apraglutide and delivering sustained profits and cash flow,” and highlighted Q1 execution across each.…
Earnings Call Insights: Natera (NTRA) Q1 2026 Management view "We posted revenues of $697 million in Q1, 39% growth over last year." (CEO & Director Steve Chapman) "Q1 was our first to deliver 1 million units in a single quarter
Earnings Call Insights: Iovance Biotherapeutics (IOVA) Q1 2026 Management View "During the first quarter of 2026, we drove Amtagvi adoption, advanced our development pipeline, and streamlined costs and efficiencies," said "First quarter revenue grew approximat…
Earnings Call Insights: argenx SE (ARGX) Q1 2026 Management View “Today is her first official day on the job,” Beth DelGiacco said, introducing “Karen Massey, our new Chief Executive Officer.” “Near term, we see continued growth with VYVGART across both MG
Earnings Call Insights: Akebia Therapeutics (AKBA) Q1 2026 Management view "We are very pleased and excited by the start to 2026" (CEO, President & Director John Butler), highlighting three execution priorities: "drive the near-term launch performance of V…
Earnings Call Insights: DiaMedica Therapeutics (DMAC) Q1 2026 Management View "We are pleased with the progress we've made so far in 2026 as we continue to advance DM199 across both our preeclampsia and acute ischemic stroke programs," said Dietrich Pauls (Pre…